Flinton Capital Management LLC increased its position in shares of Envision Healthcare Co. (NYSE:EVHC) by 58.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,512 shares of the company’s stock after purchasing an additional 3,152 shares during the period. Flinton Capital Management LLC’s holdings in Envision Healthcare were worth $294,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. CIBC World Markets Inc. purchased a new position in Envision Healthcare in the fourth quarter valued at about $208,000. CENTRAL TRUST Co increased its holdings in Envision Healthcare by 79.7% in the fourth quarter. CENTRAL TRUST Co now owns 6,626 shares of the company’s stock valued at $229,000 after buying an additional 2,939 shares in the last quarter. Alps Advisors Inc. purchased a new position in Envision Healthcare in the fourth quarter valued at about $235,000. M&T Bank Corp increased its holdings in Envision Healthcare by 33.6% in the fourth quarter. M&T Bank Corp now owns 6,818 shares of the company’s stock valued at $235,000 after buying an additional 1,716 shares in the last quarter. Finally, Parametrica Management Ltd purchased a new position in Envision Healthcare in the fourth quarter valued at about $236,000.
EVHC has been the subject of a number of research analyst reports. Jefferies Group set a $46.00 target price on shares of Envision Healthcare and gave the company a “buy” rating in a report on Thursday, March 15th. Robert W. Baird set a $45.00 target price on shares of Envision Healthcare and gave the company a “buy” rating in a report on Monday, February 26th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $37.00 target price on shares of Envision Healthcare in a report on Friday, January 5th. Stephens reaffirmed a “hold” rating and issued a $34.00 target price on shares of Envision Healthcare in a report on Wednesday, January 10th. Finally, ValuEngine cut shares of Envision Healthcare from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $42.57.
Shares of Envision Healthcare Co. (NYSE:EVHC) opened at $37.53 on Friday. The company has a market cap of $4,632.64, a P/E ratio of 14.19, a PEG ratio of 0.96 and a beta of 0.48. Envision Healthcare Co. has a 1 year low of $23.77 and a 1 year high of $66.39. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.40 and a quick ratio of 3.38.
Envision Healthcare (NYSE:EVHC) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.45 by $0.14. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.97 billion. Envision Healthcare had a negative net margin of 2.52% and a positive return on equity of 4.62%. The company’s quarterly revenue was up 68.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.15 earnings per share. sell-side analysts predict that Envision Healthcare Co. will post 3.34 EPS for the current fiscal year.
About Envision Healthcare
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.
Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.